The Federal Circuit has denied the petitions for panel rehearing and for rehearing en banc in Amgen v. Sandoz. The order denying the petitions is available here.
Related Content
- Big Molecule WatchMay 3, 2024
FDA Updates Draft Guidance on Promotional Communications of Prescription Biologics and Biosimilars
- Big Molecule WatchMay 2, 2024
Accord BioPharma, Inc. Announces FDA Approval of HERCESSI (trastuzumab-strf)
- Big Molecule WatchMay 1, 2024
PTAB Issues Final Written Decisions Finding Claims of Recombinant Lentiviral Vector Patents Valid
- Big Molecule WatchApril 30, 2024
Biosimilar Approval Updates in Europe and China
- Big Molecule WatchApril 29, 2024
GSK Sues Pfizer, Pharmacia & Upjohn & BioNTech for Infringing mRNA Vaccine Patents
- Big Molecule WatchApril 29, 2024
Moderna Litigation Against BioNTech and Pfizer Stayed Pending IPR
- Big Molecule WatchApril 26, 2024
Alvotech Announces Positive Topline Results From Confirmatory Clinical Study for its Proposed Golimumab Biosimilar
- Big Molecule WatchApril 23, 2024
FDA Approval of Alvotech/Teva Ustekinumab Biosimilar
- Awards and RankingsSeptember 25, 2023
Goodwin Named an LMG Life Sciences Life Cycle Firm for the Twelfth Consecutive Year
- Awards and RankingsOctober 4, 2022
LMG Recognizes Goodwin Lawyers and Practices for Excellence in Life Sciences
- Press ReleaseNovember 17, 2021
Goodwin Releases Update to its Comprehensive Guide to Biosimilars Litigation and Regulation in the U.S.
- Awards and RankingsOctober 26, 2021
Goodwin Named an LMG Life Sciences Life Cycle Firm for the Tenth Consecutive Year
- Press ReleaseJune 28, 2021
Goodwin Adds Life Sciences and Healthcare Litigation Partner William Jackson
- EventsDecember 5, 2020
China's Patent Linkage System: Can Strategies that Work in the U.S. System Be Applied to China?
- Awards and RankingsOctober 5, 2020
Goodwin Named An LMG Life Sciences Life Cycle Firm For The Ninth Consecutive Year
- Speaking EngagementsSeptember 23, 2020
ACI's 11th Summit on Biosimilars & Innovator Biologics